trending Market Intelligence /marketintelligence/en/news-insights/trending/z-mvssbsx1p3x1bswqqqtq2 content esgSubNav
In This List

Dr. Reddy's secures expedited appeal in Indivior opioid therapy lawsuit

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Dr. Reddy's secures expedited appeal in Indivior opioid therapy lawsuit

Dr. Reddy's Laboratories Ltd. has secured an expedited appeal of a preliminary injunction barring the Indian drugmaker from relaunching a generic version of Indivior PLC's opioid addiction therapy Suboxone.

The U.S. Court of Appeals for the Federal Circuit granted in part the motion and will now hear the case the first week of October, Indivior announced in a July 30 press release. The drug, also known as buprenorphine and naloxone, can treat opioid dependence in combination with counseling and psychosocial support, the company said.

Richmond, Va.-based Indivior has charged that Dr. Reddy's version of the medicine infringes on its patent for Suboxone. Earlier in July, the U.S. District Court for the District of New Jersey granted Indivior a preliminary injunction against Dr. Reddy's blocking a relaunch of a generic version of the drug.

The pharmaceutical company said it will continue to defend its patent rights against Dr. Reddy's appeal and another lawsuit filed in the District of New Jersey related to three other patents.

In light of the court's decision, Indivior will conduct a review of the launch timing for its recently approved schizophrenia treatment Perseris and will provide further information by Nov. 1, when the company will release its third-quarter earnings results.